• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Alterity Therapeutics Limited

    5/5/25 2:03:05 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    ALTERITY THERAPEUTICS LIMITED

    (Name of Issuer)


    American Depositary Shares, each representing 600 Ordinary Shares

    (Title of Class of Securities)


    Q02676106

    (CUSIP Number)


    04/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    Q02676106


    1Names of Reporting Persons

    JPMORGAN CHASE & CO.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    366,034,937.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    366,034,937.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    366,034,937.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ALTERITY THERAPEUTICS LIMITED
    (b)Address of issuer's principal executive offices:

    Level 14 350 Collins Street Melbourne C3 VIC 3000
    Item 2. 
    (a)Name of person filing:

    JPMORGAN CHASE & CO.
    (b)Address or principal business office or, if none, residence:

    383 Madison Avenue, New York, NY 10179
    (c)Citizenship:

    DE
    (d)Title of class of securities:

    American Depositary Shares, each representing 600 Ordinary Shares
    (e)CUSIP No.:

    Q02676106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    366034937
    (b)Percent of class:

    4.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    366034937

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    366034937

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    J.P. Morgan Securities Australia Limited; J.P. Morgan Securities PLC
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JPMORGAN CHASE & CO.
     
    Signature:Rachel Tsvaygoft
    Name/Title:Vice President
    Date:05/05/2025
    Get the next $ATHE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHE

    DatePrice TargetRatingAnalyst
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    12/12/2024$8.00Buy
    Maxim Group
    8/20/2021$4.00Speculative Buy
    Benchmark
    More analyst ratings

    $ATHE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advance into Phase 3. We accomplished this mission and then some. Results from the Phase 2 trials were resoundingly favourable with data demonstrating the drug to be safe and well-tolerated

    1/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

    MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia's best healthcare companies.  Presentation details AUSTRALIA PARTICIPANTS:Date:Wednesday, 19 November 2025Time:1:30 p.m. AEDT (Sydney/Melbourne) UNITED STATES PARTICIPANTS:Date:Tuesday, 18 November 2025Time:6:30 p.m. Pacific Time 9:30 p.m. Easte

    11/12/25 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    SEC Filings

    View All

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    1/30/26 7:59:40 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    1/20/26 9:56:00 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    1/15/26 6:31:43 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alterity Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

    2/3/25 7:02:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Alterity Therapeutics with a new price target

    Maxim Group initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $8.00

    12/12/24 8:39:51 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benchmark initiated coverage on Alterity Therapeutics with a new price target

    Benchmark initiated coverage of Alterity Therapeutics with a rating of Speculative Buy and set a new price target of $4.00

    8/20/21 7:25:55 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

    MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.  Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable us to advance into Phase 3. We accomplished this mission and then some. Results from the Phase 2 trials were resoundingly favourable with data demonstrating the drug to be safe and well-tolerated

    1/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

    MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), has announced the appointment of Abby Macnish Niven as Alterity's Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024. The Board and Management of Alterity thank Phillip for his valuable contributions over the past several years and appreciate the foundation he helped establish. Ms Macnish Niven was appointed as CFO on 30 September 2024 and has extensive experience in private wealth man

    11/19/24 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

    SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

    10/31/22 5:29:16 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

    SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

    8/26/22 5:16:24 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

    SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

    8/1/22 5:21:53 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care